Press Room

13th DPI Symposium

Start
Thursday, November 24, 2022 - 09:00
Location: Toyama, Japan

 

Schedule your meeting today with Yasushi Usuda - Regional Sales Director
yasushi-usuda-photo
 

 

Let’s discuss your project together.

 

Eunice Costa, R&D Director – Inhalation and Advanced Drug Delivery, will be a speaker at the symposium.

 

  • Title: High Dosage DPI - Formulation and process development considerations
  • Abstract: The inhalation route of administration presents several advantages, and in the last years the drug loads administered to the lung have increased more than 10 times for drugs such as antibiotics and biopharmaceuticals. The increase in dose comes with manufacturing and delivery challenges for both small and large molecules - the generation of a stable aerosol able to reach the lungs while preserving the integrity of the active ingredient, rendering it safe and effective. In the presentation the in house strategies for the manufacturing and pulmonary delivery of high dosages will be explored, from particle engineering of crystalline fine particles to spray-dried formulations, coupled with Hovione devices. This presentation will showcase the most promising high dosage formulation strategies with focus on particle engineering methods for dry powder inhalation such as spray drying.

 

Schedule a meeting today!

 

 

Also in the Press Room

See All

Integrated approach simplifies development, reduces risk, and supports scalable manufacturing. Hovione and Industrial Design Consultancy Ltd.’s (IDC) lead single-use nasal dry powder device is now available for commercial partnerships. Hovione and IDC have completed the device design and established initial device manufacturing and supply capability, enabling pharmaceutical partners to leverage existing capsule filling infrastructure. This approach simplifies development, reduces cost and risk, and helps shorten timelines to the clinic and commercialization. “This milestone marks an important step in the evolution of our collaboration with IDC — from device innovation to a fully integrated intranasal drug delivery platform,” said Márcio Temtem, Ph.D., Vice President, Strategic Business Management, Hovione. “As the industry looks for faster, more reliable ways to bring complex therapies to patients, integration becomes critical. By bringing together nasal particle engineering science, formulation manufacturing and filling, and device technologies into a single offering, we enable a more seamless and predictable development journey, accelerating the path to market for intranasal therapies.” The nasal delivery device enables broad and targeted nasal deposition flexibility while delivering maximum usability and reliability. With a patented design and manufacturing process established, the platform is available for partnering with pharmaceutical companies on an exclusive basis as part of Hovione’s integrated offering for inhalation and nasal drug development and manufacturing. Additionally, IDC’s Managing Director, Stephen Knowles Ph.D., said the companies are now “well-advanced” with the development of a multi-use device to support an even wider range of therapies and patient needs. Read the full article at ContractPharma.com    

Press Clipping

Hovione, IDC Launch Intranasal Drug Delivery Platform

May 07, 2026